<DOC>
	<DOCNO>NCT00434057</DOCNO>
	<brief_summary>The purpose clinical trial demonstrate MelaFind® , new instrument use machine vision non-invasive early detection cutaneous pigment malignant melanoma , safe effective . MelaFind® acquire digital image lesion illumination different spectral band , visible near infrared , automatically analyzes image . Diagnostic accuracy MelaFind® study dermatologist evaluate . The reference standard final interpretation lesion central dermatohistopathology .</brief_summary>
	<brief_title>Evaluation Pigmented Skin Lesions With MelaFind ( R ) System</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pigmentation Disorders</mesh_term>
	<criteria>The lesion pigment ( i.e. , melanin , keratin , blood ) Clinical management lesion examine dermatologist either biopsy lesion toto , 3month followup lesion The diameter pigment area 2 22 millimeter The lesion accessible MelaFind handheld image device The patient , legally authorize representative , consent participate study sign Informed Consent Form The patient know allergy isopropyl alcohol The lesion previously biopsied , excise , traumatize The skin intact ( e.g. , open sore , ulcer , bleed ) The lesion within 1 cm eye The lesion mucosal surface ( e.g. , lip , genitals ) The lesion palmar hand The lesion plantar foot The lesion nail The lesion locate area visible scar The lesion contain foreign matter ( e.g. , tattoo , splinter , marker )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pigmented Skin Lesions</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>MelaFind</keyword>
</DOC>